Karyopharm initiated with a Buy at B. Riley FBR. B. Riley FBR analyst Harshita Polishetty started Karyopharm Therapeutics with a Buy rating and $23 price target. https://thefly.com/landingPageNews.php?id=2830607
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.